InteKrin Therapeutics Announces Appointment of Geoffrey M. Parker as Chief Business...

InteKrin Therapeutics Announces Appointment of Geoffrey M. Parker as Chief
Business Officer

LOS ALTOS, Calif., July 13 /PRNewswire/ -- InteKrin Therapeutics Inc.
announced today that Geoffrey M. Parker has joined InteKrin as Chief Business
Officer. Most recently, Mr. Parker served as a Managing Director and Partner
in the Investment Banking Division of Goldman, Sachs & Co. Over the past ten
years, Mr. Parker led Goldman Sachs' West Region Healthcare Investment Banking
practice during which time he advised many of the biotechnology industry's
leading companies.

"We are very pleased to have such an eminent healthcare business professional
join us," said Denny Lanfear, InteKrin Chief Executive. "The expertise,
insights and depth of business experience Geoff brings are complementary to
the InteKrin team's capabilities as world class drug developers and
scientists."

"InteKrin is an exciting opportunity and INT131 presents significant promise
for patient benefit," said Geoff. "INT131 has the potential to be a
breakthrough product, and I am delighted to be part of the InteKrin team as we
complete our Phase 2 work and plan to advance into Phase 3."

About INT131
INT131 is a next-generation insulin sensitizer currently in Phase 2b testing
that addresses insulin resistance, a key etiological feature in the onset and
subsequent progression of type 2 diabetes. Treating and improving insulin
sensitivity in diabetic patients by activating PPAR-gamma is an important
therapeutic tool for physicians, providing powerful glucose control and
durability of effect. As a SPPARM, INT131 selectively modulates PPAR-gamma,
thereby enabling the separation of PPAR gamma anti-diabetic efficacy from the
well recognized TZD side effects.

About InteKrin (www.InteKrin.com)
InteKrin Therapeutics is a privately-held clinical-stage drug development
company focused on diabetes, obesity and metabolic disease. InteKrin's
business strategy is to build a robust portfolio of high value products by
in-licensing clinical-stage therapeutic candidates that address significant
unmet medical needs and rapidly move them through critical development stages.
InteKrin's team of world-class scientific and medical experts includes
veterans from several successful BioPharma organizations, internationally
recognized experts in nuclear receptors and metabolism, top scientists
formerly with the Food and Drug Administration and key clinical and
commercialization leaders.

SOURCE InteKrin Therapeutics Inc.

Alison Wong of InteKrin Therapeutics Inc., +1-650-941-5501